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Background: We previously reported on subtypes of polypoidal choroidal vasculopathy (PCV), and categorized PCV
as polypoidal choroidal neovascularization (CNV) and typical PCV. The aim of this study was to clarify whether
complement component 2 (C2) and complement factor B (CFB) genotypes are associated with subtypes of
polypoidal choroidal vasculopathy, such as polypoidal CNV and typical PCV.
Methods: First, we categorized 677 patients into typical age-related macular degeneration (tAMD; 250 patients), PCV
(376) and retinal angiomatous proliferation (RAP; 51). Second, we categorized 282 patients with PCV as having polypoidal
CNV (84 patients) or typical PCV (198) based on indocyanine green angiographic findings. In total, 274 subjects without
AMD, such as PCV and CNV, served as controls. A SNP (rs547154) in the C2 gene and three SNPs (rs541862, rs2072633,
rs4151667) in the CFB gene were genotyped, and case–control studies were performed in subjects with these PCV
subtypes.
Results: In tAMD, no SNPs were associated with allele distributions. In PCV, rs547154 and rs2072633 were associated with
allele distributions. RAP was only associated with rs2072633. After logistic regression analysis with adjustment for
confounding factors, tAMD, PCV and RAP were found to be associated with rs2072633.
As to PCV subtypes, there were significant differences in the distributions of rs547154, rs541862 and rs2072633 in the
case–control studies for polypoidal CNV, but not between the typical PCV and control groups. Logistic regression analysis
with adjustment for confounding factors showed the distributions of rs547154, rs541862 and rs2072633 to differ
significantly between the controls and polypoidal CNV cases and that these SNPs were protective. The A/A genotype of
rs2072633 was significantly more common in the polypoidal CNV than in the typical PCV group (p = 0.03), even with
adjustment for polyp number and greatest linear dimension.
Conclusions: PCV might be genetically divisible into polypoidal CNV and typical PCV. The C2 and CFB gene variants
were shown to be associated with polypoidal CNV. Typical PCV was not associated with variants in these genes.
Keywords: Subtypes of PCV, C2, CFB, Genetic variantsBackground
Age-related macular degeneration (AMD) is a leading
cause of blindness in Western countries and its preva-
lence is increasing in Japan [1]. AMD is thought to be a
heterogeneous multifactorial disease associated with
several environmental factors and genetic variants.
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unless otherwise stated.related to the development of AMD. Identification of
AMD susceptibility genes might increase our ability to
predict the risk of developing this disease. Complement
factor H (CFH), age-related maculopathy susceptibility
2 (ARMS2) and high-temperature requirement factor
A1 (HTRA1) have been shown to be associated with
AMD in both Japanese and Caucasian patients [4-7]. In
addition, complement component 2(C2) and comple-
ment factor B (CFB) known as activators of alternative
complement cascades are reportedly related to AMD in
Caucasians [8]. Both were reported to be protectiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Typical PCV. Neither feeder nor draining vessels were visible
in the early phase of indocyanine green angiography. The network is
composed of a small number of vessels with a polypoidal lesion.
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of PCV have found no association between either C2 or
CFB and PCV [11,12]. Nakata et al. reported that, in the
Japanese population, C2 and CFB are associated with
both PCV and typical AMD (tAMD) [13].
Polypoidal choroidal vasculopathy (PCV), characterized
by a branching vascular network with polypoidal lesions
detectable by indocyanine green angiography (IA) [14], is
included among the forms of exudative AMD in Japan
[15]. Our group previously reported on subtypes of PCV,
and categorized PCV as polypoidal choroidal neovasculari-
zation (CNV) and PCV in the narrow sense (also referred
to as typical PCV) [16]. In the first type, both feeder and
draining vessels are visible on IA and network vessels are
numerous. This type is thought to be the representative
form of CNV beneath the retinal pigment epithelium. In
the second group, neither feeder nor draining vessels are
detectable and the number of network vessels is small.
This type is thought to represent an abnormality of the
choroidal vasculature based on hyaline arteriosclerosis
[17]. We also showed that there are differences in these
two types classified according to IA and optic coherence
tomography findings [18]. Genetically, we demonstrated
an association between the ARMS2 gene and these two
types of PCV [19]. There was a significant ARMS2 gene
difference in case–control studies of polypoidal CNV, but
no difference between the typical PCV and control groups.
This observation suggests that PCV might be genetically
divisible into polypoidal CNV and typical PCV.
The possibility of dividing PCV into two types has been
raised by other investigators. Okubo et al. reported that
PCV can be divided into two types; the small-short and
large-long types, but the clinical features in their report dif-
fered from those described by our group [20]. Miki et al. re-
cently advocated dividing PCV into polypoidal lesions with
a clear branching vascular network and polypoidal lesions
without such a vascular network [21]. After classifying PCV
into two types based on IA findings, we conducted ARMS2
and CFH genotyping for our patients. The results were
highly consistent with our report showing typical PCV to
be unrelated to the ARMS2 gene.
The present study aimed to investigate whether there is
an association between the C2 or the CFB gene and any of
the subtypes of PCV. To our knowledge, this is the first




Six hundred and seventy-seven patients diagnosed as
having AMD at Nihon University Surugadai Hospital in
Tokyo were enrolled in this study between 2008 and
2010 (472 men, 205 women; mean age 72.11 years). We
then categorized AMD as tAMD, PCV and RAP basedon IA and color photograph. (tAMD; 187 men, 63 women,
PCV; 266 men, 110 women, RAP;19 men, 32 women)
Furthermore, we also classified PCV patients into
groups with two different types of PCV, polypoidal CNV
and typical PCV. Two hundred and eighty-two (195 men,
87 women; mean age 70.0 ± 8.8 years) out of 376 patients
were enrolled after classification based on whether or not
both feeder and draining vessels were seen on IA (Figures 1
and 2). Due to unclear IA findings, we could not classify
the remaining 94 patients. Eighty-four patients were diag-
nosed with polypoidal CNV, 198 with typical PCV. Polyp
numbers and greatest linear dimension (GLD) were deter-
mined by IA at the first visit.
Information on hypertension, diabetes mellitus and
smoking was obtained from medical histories collected for
each patient. Smokers were defined as current or former
smokers, whereas non-smokers were defined as subjects
with no previous or current smoking history.
In total, 274 subjects free of AMD (110 men, 164
women; mean age 72.9 ± 7.4 years) served as controls.
There were no remarkable findings on fundus examina-
tions of the controls. Informed consent was obtained from
each individual as per the protocol approved by the Hu-
man Studies Committee of Nihon University. This investi-
gation was performed according to the guidelines of the
Declaration of Helsinki.
Genotyping
DNA was extracted from peripheral blood leukocytes by
the phenol and chloroform extraction method [22,23].
Genotyping was performed using the TaqMan® SNP
Genotyping Assay (Applied Biosystems Inc. Foster City,
Figure 2 Polypoidal CNV. Both feeder and draining vessels were
observed in the early phase of indocyanine green angiography.
Large numbers of network vessels were seen to be fluorescing in an
umbrella-like configuration. Several of the polypoidal lesions were
dilatations of marginal tortuous vessels.
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formed using the Taq amplification method [22,23].
We targeted C2 rs547154(IVS10), and CFB rs541862,
rs2072633(IVS17) and rs4151667(H9L), all of which were
identified as having positive associations with AMD in
prior studies [11,13].
Plates were read on the SDS 7700 instrument with
the end-point analysis mode of the SDS version
1.6.3 software package (Applied Biosystems). Geno-
types were determined visually based on the dye-
component fluorescent emission data depicted in
the X-Y scatter-plot of the SDS software. Genotypes
were also determined automatically by the signal
processing algorithms of the software [22,23].Table 1 Characteristics of study participants
Ca
Total AMD P vs. control Typical AMD P vs. contro
Subjects, n 677 250
Male/female 472/205 <0.0001* 187/63 <0.0001*
Age 72.1(±8.7) 0.157 73.6(±7.5) 0.289
HT 39% 0.308 41% 0.658
DM 11% <0.0001* 14% 0.079
Smoker 35% <0.0001* 37% <0.0001*
p-values reflect comparisons between each of the case groups and the control grou
*p < 0.05.Statistical analysis
Data are shown as means ± SD. Differences between the
PCV subtype and control groups were assessed by ana-
lysis of variance (ANOVA) followed by Fisher’s pro-
tected least significant difference test. Hardy-Weinberg
equilibrium was assessed by chi-squared analysis. The
overall distribution of alleles was analyzed using 2 × 2
contingency tables. The distribution of the genotypes
between patient groups and controls was tested using a
2-sided Fisher’s exact test and multiple logistic regres-
sion analysis. After Bonferroni correction, statistical sig-
nificance was set at p < 0.0125.
Based on the genotype data of the genetic variations,
linkage disequilibrium (LD) analyses and a haplotype-
based case–control study were carried out using the
expectation maximization algorithm with the SNPA-
lyze software program ver3.2 (Dynacom, Yokohama,
Japan). |D’| values > 0.5 were used to assign SNP loca-
tions to one haplotype block. The frequency distribu-
tion of occurrence of the haplotypes was calculated by
χ2 analyses.Results
The clinical features of AMD patients and the control
group are shown in Table 1. Distributions of genotypes
and alleles are shown in Table 2. Four variants were in
Hardy-Weinberg equilibrium in the control group (data
not shown, p > 0.05). There were significant differences
in PCV the allele distributions of rs547154 (C2 gene)
and rs2072633 (CFB gene) between the PCV group and
the controls. The RAP allele distribution of rs2072633
differed significantly between the RAP group and the
controls. The tAMD group showed no difference from
the controls.
The results of logistic regression analysis, with adjust-
ment for confounding factors, including age, gender
and risk factors, are shown in Table 3. This analysis
was performed for the dominant or recessive genotype
models showing significant results, as presented inse
Control
l PCV P vs. control RAP P vs. control
376 51 274
266/110 <0.0001* 19/32 0.757 110/164
70.0(±8.9) <0.0001* 80.9(±6.8) <0.0001* 72.9(±7.4)
38% 0.226 41% 0.878 43%
9% 0.081 6% 0.016* 20%
36% <0.0001* 16% 84% 18%
p, calculated using Fisher’s exact test.
Table 2 Genotype and allele distributions in AMD patients and control group
Total
Total AMD patients tAMD PCV RAP Control
n % p-value n % p-value n % p-value n % p-value n %
rs547154 Genotype G/G 601 88.8% 0.024 221 88.4% 0.192 335 89.1% 0.053 45 88.2% 0.561 229 83.6%
T/G 74 10.9% 28 11.2% 40 10.6% 6 11.8% 41 15.0%
T/T 2 0.3% 1 0.4% 1 0.3% 0 0.0% 4 1.5%
Dominant model G/G 601 88.8% 0.032 221 88.4% 0.132 335 89.1% 0.046 45 88.2% 0.530 229 83.6%
TG + TT 76 11.2% 29 11.6% 41 10.9% 6 11.8% 45 16.4%
Recessive model TT 2 0.3% 0.061 1 0.4% 0.375 1 0.3% 0.168 0 0.0% 0.385 4 1.5%
Allele G 1276 94.2% 0.004* 470 94.0% 0.026 710 94.4% 0.005* 96 94.1% 0.260 499 91.1%
T 78 5.8% 30 6.0% 42 5.6% 6 5.9% 49 8.9%
rs541862 Genotype T/T 600 88.6% 0.054 221 88.4% 0.246 335 89.1% 0.078 44 86.3% 0.715 229 83.6%
T/C 75 11.1% 28 11.2% 40 10.6% 7 13.7% 42 15.3%
C/C 2 0.3% 1 0.4% 1 0.3% 0 00.0% 3 1.1%
Dominant model T/T 600 88.6% 0.038 221 88.4% 0.132 335 89.1% 0.046 44 86.3% 0.835 229 83.6%
TC + CC 77 11.4% 29 11.6% 41 10.9% 7 13.7% 45 16.4%
Recessive model C/C 2 0.3% 0.147 1 0.4% 0.625 1 0.3% 0.315 00.0% 0.453 3 1.1%
TC + TT 675 99.7% 249 99.6% 375 99.7% 51 100.0% 271 98.9%
Allele T 1275 94.2% 0.025 470 94.0% 0.099 710 94.4% 0.027 95 93.1% 0.698 500 91.2%
C 79 5.8% 30 6.0% 42 5.6% 7 6.9% 48 8.8%
rs2072633 rs2072633 G/G 115 17.0% 0.0024* 48 19.2% 0.120 61 16.2% 0.0026* 6 11.8% 0.048 69 25.2%
G/A 323 47.7% 120 48.0% 178 47.3% 25 49.0% 134 48.9%
A/A 239 35.3% 82 32.8% 137 36.4% 20 39.2% 71 25.9%
Dominant model G/G 115 17.0% 0.0038* 48 19.2% 0.101 61 16.2% 0.0048* 6 11.8% 0.037 69 25.2%
GA + AA 562 83.0% 202 80.8% 315 83.8% 45 88.2% 205 74.8%
Recessive model A/A 239 35.3% 0.0051* 82 32.8% 0.083 137 36.4% 0.0045* 20 39.2% 0.052 71 25.9%
GA + GG 438 64.7% 168 67.2% 239 63.6% 31 60.8% 203 74.1%
Allele G 553 40.8% 0.0005* 216 43.2% 0.037 300 39.9% 0.0005* 37 36.3% 0.013 272 49.6%
A 801 59.2% 284 56.8% 452 60.1% 65 63.7% 276 50.4%
rs4151667 Genotype T/T 653 96.5% 0.386 241 96.4% 0.514 363 96.5% 0.412 49 96.1% 0.797 261 95.3%
A/T 24 3.5% 9 3.6% 13 3.5% 2 3.9% 13 4.7%
A/A 0 0.0% 0 0.0% 0 0.0% 0 0.0% 0 0.0%
Dominant mode T/T 653 96.5% 0.459 241 96.4% 0.664 363 96.5% 0.424 49 96.1% 0.797 261 95.3%



















Table 2 Genotype and allele distributions in AMD patients and control group (Continued)
Recessive model A/A 0 0.0% - 0 0.0% - 0 0.0% - 0 0.0% - 0 0.0%
AT + TT 677 100.0% 250 100.0% 376 100.0% 51 100.0% 274 100.0%
Allele T 1330 98.2% 0.461 491 98.2% 0.667 739 98.3% 0.429 100 98.0% 0.779 535 97.6%
A 24 1.8% 9 1.8% 13 1.7% 2 2.0% 13 2.4%
AMD; age related macular degeneration tAMD; typical age related macular degeneration PCV; polypoidal choroidal vasculopathy RAP; retinal angiomatous proliferation.
P- values are for the comparison between cases and controls.



















Table 3 Logistic regression analysis with adjustment for confounding factors


















rs547154 dominant model 0.044* 0.176 0.62 0.39-0.99 0.186 0.744 0.103 0.412 0.626 1.000
recessive model 0.051 0.204 0.159 0.636 0.105 0.420 -
rs541862 dominant model 0.049* 0.196 0.63 0.39-0.99 0.169 0.676 0.119 0.476 0.877 1.000
recessive model 0.133 0.532 0.232 0.928 0.213 0.852 0.996 1.000
rs2072633 dominant model 0.0003* 0.001** 0.49 0.33-0.73 0.042* 0.168 0.59 0.36-0.99 0.001* 0.004** 0.048* 0.192 0.35 0.13-0.99
recessive model 0.031* 0.124 0.68 0.48-0.97 0.312 1 0.010* 0.04** 0.46 0.29-0.74 0.423 1.000
rs4151667 dominant model 0.273 1 0.952 1 0.270 1 0.59 0.40-0.88 0.769 1.000
recessive model - - - -
Logistic regression analysis was performed for each genotype with adjustment for confounding factors (age, gender, hypertension, diabetes mellitus and smoking).
PCV; polypoidal choroidal vasculopathy.
OR; odds ratios CI; confidence intervals.
p-values are for the comparisons between cases and controls.
p-values for genotypes were calculated using Fisher’s exact test. *p < 0.05B.
Bonferroni correction was performed for each of the genotypes. **p < 0.05.
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quencies in patient groups in case–control studies. The
rs2072633 distribution of the controls differed significantly
from those of the tAMD, PCV and RAP groups. After
Bonferroni correction, only PCV showed significant differ-
ence in this SNP.
The clinical features of PCV patients and the control
group are shown in Table 4. There were significant dif-
ferences in polyp numbers and GLD, both of which were
greater in polypoidal CNV group.
Distributions of genotypes and alleles of the four var-
iants are shown in Table 5. Four variants were in
Hardy-Weinberg equilibrium in the control group
(data not shown, p > 0.05). There were significant dif-
ferences in all genotype models and allele distributions
of rs547154 (C2 gene), rs541862 and rs2072633 (CFB
gene), but not rs4151667, between the polypoidal CNV
group and the controls. However, there were no signifi-
cant differences in any genotype model or allele distri-
bution for any of the SNPs between the typical PCV
and control groups.
The results of logistic regression analysis, with ad-
justment for confounding factors, including age, gen-
der and risk factors, are shown in Tables 6 and 7. This
analysis was performed for the dominant or recessive
genotype models showing significant results, as pre-
sented in Table 5. Susceptibility genotypes were those
with high frequencies in patient groups in case–control
studies. The distributions of rs541862, rs547154 and
rs2072633 differed significantly between the controls
and the polypoidal CNV group. After Bonferroni cor-
rection, the distribution of rs2072633 remained signifi-
cant only for polypoidal CNV, i.e. not for typical PCV.
Logistic regression analysis was also performed to
compare the polypoidal CNV and typical PCV groups.
The only significant difference, after adjusting for con-
founding factors such as polyp numbers and GLD, wasTable 4 Characteristics of PCV participants
Total PCV P vs. control Polypoidal CNV P vs.
Subjects, n 282 84
Male/female 195/87 <0.0001* 63/21 <0.0
Age(±SD) 70.0(±8.7) <0.0001* 68.8(±8.9) <0.0
Hypertension 39% 0.390 38% 0
Diabetes 9% <0.0001* 10% 0.0
Smoking 33% <0.0001* 37% <0.0
Number of polyps - 4.17
GLD, mm - 3.78
p-values reflect comparisons between each of the case groups and the control grou
PCV; polypoidal choroidal vasculopathy CNV; choroidal neovascularization GLD; grein rs2072633. After Bonferroni correction, no signifi-
cant difference remained.
LD was assessed for three SNPs in CFB, and the dis-
tribution of estimated haplotype frequencies is shown
in Tables 8 and 9. The T-A-T(rs541862-rs2072633-
rs4151667) and C-G-T haplotypes both showed strong
associations in the polypoidal CNV, typical PCV and
control groups. Furthermore, the T-A-A haplotype
differed significantly between polypoidal CNV and
typical PCV.
Discussion
ARMS2 genes, especially the rs10490924 of CFH and
rs1061170, are both known as PCV susceptibility
genes [24,25]. On the other hand, our group previ-
ously reported that typical PCV did not correlate sig-
nificantly with rs10490924 [19]. This result raised the
possibility of two distinct genetic types of PCV. In the
present study, the C2 gene and the CFB gene were
also found to be associated with polypoidal CNV, in
terms of both genotypes and allele distributions. No
associations with typical PCV were detected. These
results indicate the C2 and CFB genes to also be asso-
ciated with PCV subtypes. Our group recently re-
ported typical PCV to have the features of abnormal
choroidal vessels and that polypoidal CNV also has
features of neovascularization. The differences be-
tween tAMD and polypoidal CNV were that the latter
had polypoidal lesion detectable by IA, while tAMD
had no polypoidal lesion. Furthermore, polypoidal
CNV is characterized by a larger GLD and more
polyps than typical PCV [18]. As polypoidal CNV has
neovascularization features, the ARMS2 gene might
be highly associated with neovascularization. Though
there are reports describing rs4151667 as being asso-
ciated with AMD, the minor allele homozygous fre-
quency was very low in all of these reports [9,10]. In thisCase
Control
control P vs. typical PCV Typical PCV P vs. control
198 274
001* 0.205 132/66 <0.0001* 110/164
001* 0.130 70.5(±8.7) <0.0001* 72.9(±7.4)
.45 0.792 40% 0.509 43%
32* 0.649 8% <0.0001* 20%
001* 0.406 31% 0.001* 18%
<0.0001* 1.95 -
<0.0001* 2.78 -
p, calculated using Fisher’s exact test *p < 0.05.
atest linear dimension SD; standard deviation.
Table 5 Genotype and allele distributions in PCV patients and control group
Total PCV patients Polypoidal CNV Typical PCV Control
Number % p-value Number % p-value Number % p-value Number %
rs547154 Genotype G/G 255 90.4% 80 95% 175 88% 229 84%
T/G 26 9.2% 0.0400 4 5% 0.023 22 11% 0.276 41 15%
T/T 1 0.4% 0 0% 1 1% 4 1%
Dominant model G/G 255 90.4% 0.016 80 95% 0.007* 175 88% 0.142 229 84%
TG + TT 27 9.6% 4 5% 23 12% 45 16%
Recessive model TT 1 0.4% 0.168 0 0% 0.265 1 1% 0.317 4 1%
TG + GG 281 99.6% 84 100% 197 99% 270 99%
Allele G 536 95.0% 0.009* 164 98% 0.004* 372 94% 0.110 499 91%
T 28 5.0% 4 2% 24 6% 49 9%
rs541862 Genotype T/T 255 90.4% 80 95% 175 88% 229 84%
T/C 26 9.2% 0.049 4 5% 0.023 22 11% 0.318 42 15%
C/C 1 0.4% 0 0% 1 1% 3 1%
Dominant model T/T 255 90.4% 0.016 80 95% 0.007* 175 88% 0.142 229 84%
TC + CC 27 9.6% 4 5% 23 12% 45 16%
Recessive model C/C 1 0.4% 0.302 0 0% 0.336 1 1% 0.490 3 1%
TC + TT 281 99.6% 84 100% 197 99% 271 99%
Allele T 536 95.0% 0.013 164 98% 0.004* 372 94% 0.137 500 91%
C 28 5.0% 4 2% 24 6% 48 9%
rs2072633 Genotype G/G 50 17.7% 13 15% 37 19% 69 25%
G/A 131 46.5% 0.017 34 40% 0.005* 97 49% 0.149 134 49%
A/A 101 35.8% 37 44% 64 32% 71 26%
Dominant model G/G 50 17.7% 0.032 13 15% 0.064 37 19% 0.095 69 25%
GA + AA 232 82.3% 71 85% 161 81% 205 75%
Recessive model A/A 101 35.8% 0.012* 37 44% 0.002* 64 32% 0.128 71 26%
GA + GG 181 64.2% 47 56% 134 68% 203 74%
Allele G 231 41.0% 0.004* 60 36% 0.002* 171 43% 0.055 272 50%
A 333 59.0% 108 64% 225 57% 276 50%
rs4151667 Genotype T/T 273 96.8% 81 96% 192 97% 261 95%
A/T 9 3.2% 0.348 3 4% 0.649 6 3% 0.350 13 5%
A/A 0 0.0% 0 0% 0 0% 0 0%
Dominant model T/T 273 96.8% 0.348 81 96% 0.649 192 97% 0.350 261 95%
AT + AA 9 3.2% 3 4% 6 3% 13 5%
Recessive model A/A 0 0.0% - 0 0% - 0 0% - 0 0%
AT + TT 282 100.0% 84 100% 198 100% 274 100%
Allele T 555 98.4% 0.394 165 98% 0.775 390 98% 0.482 535 98%
A 9 1.6% 3 2% 6 2% 13 2%
PCV; polypoidal choroidal vasculopathy CNV; choroidal neovascularization.
p- values are for the comparison between cases and controls.
p- values for genotypes were calculated by Fisher’s exact test. (after Bonferroni correction *p < 0.0125).
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was zero, such that there was no difference between cases
and controls.
Nakata et al. reported the C2 (rs547154) and CFB
(rs541862) genes to be significantly associated with bothtAMD and PCV in the Japanese population [13]. Never-
theless, rs2072633 (CFB gene) and rs4151672 (CFB
gene) showed no correlations with either tAMD or PCV.
In the present study, we showed rs2072633 to be signifi-
cantly associated with PCV. This result indicates the
Table 6 Logistic regression analysis between cases and controls














rs547154 dominant model 0.018* 0.072 0.48 0.26-0.89 0.014* 0.056 0.22 0.05-0.86 0.139 0.556
recessive model 0.217 0.868 0.097 0.388 0.409 1.000
rs541862 dominant model 0.023* 0.092 0.49 0.26-0.91 0.015* 0.060 0.22 0.05-0.87 0.162 0.648
recessive model 0.417 1 0.131 0.524 0.646 1.000
rs2072633 dominant model 0.012* 0.048** 0.52 0.32-0.87 0.104 0.416 0.037* 0.148 0.55 0.32-0.96
recessive model 0.035* 0.140 0.63 0.41-0.96 0.009* 0.036** 0.40 0.20-0.79 0.199 0.796
rs4151667 dominant model 0.326 1 0.984 1 0.211 0.844
recessive model - - - - -
Logistic regression analysis was performed for each genotype with adjustment for confounding factors (age, gender, hypertension, diabetes mellitus and smoking).
PCV; polypoidal choroidal vasculopathy.
OR; odds ratios CI; confidence intervals.
p-values are for comparisons between cases and controls.
p-values for genotypes were calculated using Fisher’s exact test. *p < 0.05.
Bonferroni correction was performed for each of the genotypes. **p < 0.05.



















Table 7 Logistic regression analysis between polypoidal CNV and typical PCV
Polypoidal CNV
p-value vs. typical PCV (Bonferroni correction) OR 95%CI
rs547154 dominant model 0.073 0.292
recessive model 0.392 1
rs541862 dominant model 0.073 0.292
recessive model 0.392 1
rs2072633 dominant model 0.720 1
recessive model 0.038* 0.152 2.09 1.04-4.22
rs4151667 dominant model 0.915 1
recessive model - -
Logistic regression analysis was performed for each genotype with adjustment for confounding factors (age, gender, hypertension, diabetes mellitus
and smoking).
OR; odds ratios CI; confidence intervals GLD; greatest linear dimension.
p-values are for the comparisons between polypoidal CNV and typical PCV.
p-values for genotypes were calculated using Fisher’s exact test. *p < 0.05.
Bonferroni correction were performed for each genotypes. p < 0.05.
Blanks indicate that there were no siginificant differences.
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correction, tAMD was also associated with rs547154 and
rs2072633. We previously reported that polypoidal CNV
resembles tAMD, while typical PCV clearly differs from
CNV. Though not significant after Bonferroni correc-
tion, given the prior reports dividing PCV into two
types, we can reasonably speculate that the C2 and CFB
genes might be related to tAMD and polypoidal CNV
but not to typical PCV. The present C2 and CFB gene
results also are not inconsistent with this possibility.
Since typical PCV was not associated with any of the
SNPs tested, we can also speculate that typical PCV
might differ genetically from AMD.
C2 and CFB functioned as activators of the comple-
ment cascade. CFB is localized to the choroidal vascula-
ture and Bruch’s membrane [26]. Smailhodzic et al.
reported AMD patients to show increased alternative
pathway activation and elevated CFB levels [27]. Scholl
et al. also showed plasma CFB to be significantly ele-
vated in AMD patients [28]. For these reasons, AMD
might be related to CFB.
Recently, Liu et al. reported the C2-CFB-RDBP-
SKIV2L region of SNPs to be associated only with
tAMD, not with PCV. They concluded that the mecha-
nisms underlying the development of tAMD and PCVTable 8 Linkage disequilibrium map through 3 SNPs in
CFB gene
rs541862 rs2072633 rs4151667
rs541862 - 0.929 0.278
rs2072633 -0.040 - 1
rs4151667 -0.001 0.012 -
The upper right shows the D’-value, the lower left the D-value.might be different [29]. Nakashizuka et al. reported
histopathological characteristics of PCV [17]. In their re-
port, areas of PCV showed little fibrosis or granulation
as compared to those with CNV. This might indicate
that typical PCV involves less inflammation than CNV.
Since polypoidal CNV has AMD features, C2 and CFB
might be related only to polypoidal CNV.
The results presented in Table 8 show that three
of the SNPs in CFB were in LD block. Haplotypes
T-A-T and T-G-T differed significantly between the
PCV and control groups. Furthermore, T-A-T would
confer a risk for PCV, while T-G-T would be pro-
tective against PCV development. We could reason-
ably draw the same conclusion for haplotypes C-A-T
and C-G-T. These results indicate that rs2072633
might be one of the key SNPs favoring PCV
development.
There has been controversy regarding the division of
PCV into two subtypes. Tsujikawa et al. reported that if
there is risk associated with being homozygous for the
ARMS2 gene, it would be the larger GLD in PCV [30].
Their report described two types of PCV, with larger
GLD and smaller GLD. The aforementioned report by
Miki and colleagues presented results very similar to
ours, indicating the ARMS2 gene to have no association
with typical PCV [21]. These two reports also support
the assumption that the ARMS2 gene is unrelated to
PCV [17,18]. While IA findings of polypoidal CNV ap-
peared to be consistent with CNV, the histopathological
and IA features of typical PCV showed choroidal vascu-
lature abnormalities. These observations suggested poly-
poidal CNV to be genetically and histopathologically
close to tAMD, a representative form of CNV. Further-
more, typical PCV showed no association with CNV.
Table 9 Haplotype association analysis in cases and controls
Polypoidal CNV vs. control
Haplotypes %
rs541862 rs2072633 rs4151667 Polypoidal CNV Control Chi-Squ p-value
T A T 63% 42% 22.177 <0.0001*
C A T 0% 9% 14.9366 0.0001*
T G T 35% 47% 7.9166 0.0049*
C G T 2% 0% 13.5581 0.0002*
T G A 0% 2% 3.9293 0.0475*
Typical PCV vs. control
Haplotypes %
rs541862 rs2072633 rs4151667 Typical PCV Control Chi-Square p-value
T A T 57% 42% 20.5614 <0.0001*
C A T 0% 9% 34.8144 <0.0001*
T G T 37% 47% 9.3704 0.0022*
C G T 6% 0% 33.5324 <0.0001*
Polypoidal CNV vs. typical PCV
Haplotypes %
rs541862 rs2072633 rs4151667 Typical PCV Polypoidal CNV Chi-Squ p-value
T A T 57% 63% 1.5687 0.2104
C A T 0% 0% 0 1
T G T 36% 33% 0.3302 0.5656
C G T 6% 2% 3.0395 0.0813
T A A 0% 2% 7.1092 0.0077*
C A A 0% 0% 0 1
T G A 1% 0% 2.1402 0.1435
C G A 0% 0% 0 1
*p-value > 0.05 calculated by chi-square analysis.
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http://www.biomedcentral.com/1471-2415/14/83The small sample size with only one genotype is the
major limitation of this study. Further study is clearly
needed.
Conclusion
The present study is the first to examine the associations
between variants in the C2 and CFB genes and PCV sub-
types. We found the C2 and CFB genes to possibly be
genetic markers for polypoidal CNV. Furthermore, these
variants showed no associations with typical PCV. These
results suggest polypoidal CNV to have a genetic back-
ground different from that of typical PCV. Further stud-
ies are needed to examine the effects of various
treatments on PCV subtypes.
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